Skip to main content

BioNTech to Hold Digital Press Conference to Provide an Update on Omicron Variant

Written by Customer Service on . Posted in Public Companies.

MAINZ, Germany, December 8, 2021 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will hold a digital press conference on Wednesday, December 8, 2021, to present the results from initial laboratory studies which started about two weeks ago. The studies aimed to investigate the effects of the Omicron variant on COVID-19 vaccine-induced immune responses. The press conference will solely be held in a virtual format and will be conducted in English.

International digital press conference at 3.00 pm CET / 9.00 am ET
Please register here.

The conference can be streamed. Interested journalists may dial in 10 to 15 minutes before the conference starts. They will be able to submit questions via an online tool.There will be no access for journalists on-site.

Participants may also digitally access the press conference on https://biontech.de/ under “Events & Presentations” in the Investor & Media section of the website. A recording of the press conference as well as the presentation will be available under the section “Past Events” on the same day.

About BioNTech
Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bispecific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma and Pfizer.

For more information, please visit www.BioNTech.de

Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de  

Investor Relations
Sylke Maas, Ph.D.
+49 (0)6131 9084 1074
Investors@biontech.de

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.